The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration. To detect hIGF-2 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIGF-2 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
Use at an assay dependent concentration. To detect hIGF-2 by ELISA (using 100µl/well antibody solution) a concentration of at least 0.5µg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2 - 0.4 ng/well of recombinant hIGF-2.
Use at an assay dependent concentration. To yield one-half maximal inhibition of the biological activity of hIGF-2 (10.0 ng/ml), a concentration of 3.1 - 4.6 µg/ml of this antibody is required.
Use a concentration of 1 - 5 µg/ml.
Use at an assay dependent concentration.
The insulin-like growth factors possess growth-promoting activity. In vitro, they are potent mitogens for cultured cells. IGF-II is influenced by placental lactogen and may play a role in fetal development. Preptin undergoes glucose-mediated co-secretion with insulin, and acts as physiological amplifier of glucose-mediated insulin secretion. Exhibits osteogenic properties by increasing osteoblast mitogenic activity through phosphoactivation of MAPK1 and MAPK3.
Epigenetic changes of DNA hypomethylation in IGF2 are a cause of Silver-Russell syndrome (SIRS) [MIM:180860]. SIRS is a clinically heterogeneous condition characterized by severe intrauterine growth retardation, poor postnatal growth, craniofacial features such as a triangular shaped face and a broad forehead, body asymmetry, and a variety of minor malformations.
Belongs to the insulin family.
O-glycosylated with a core 1 or possibly core 8 glycan.
ICC/IF image of ab9574 stained HepG2 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab9574, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
Western blot - Anti-IGF2 antibody (ab9574)
Rabbit Anti-Human IGF-II against Human IGF-II. Antibody concentration: 0.10 ug/ml Lower limit of detection: 3.91 ng/lane Molecular Weight: 7.5 kDa Lane 1: Marker Lane 2: 250 ng Lane 3: 125 ng Lane 4: 62.5 ng Lane 5: 31.25 ng Lane 6: 15.625 ng Lane 7: 7.8 ng Lane 8: 3.9 ng
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IGF2 antibody (ab9574)This image is courtesy of an anonymous Abreview
ab9574 staining human tongue carcinoma tissue sections by IHC-P. For antigen retrieval sections were placed in a bath of 0.01M citric acid, pH6, and were heated on full power in a microwave for 5 minutes and then for a further 4 minutes. The slides were then cooled and placed in PBS, fixed with paraformaldehyde and blocked with BSA. The slides were incubated with the antibody for 18 hours. An HRP conjugated pig polyclonal antibody was used as the secondary.
IHC-P of normal human placenta stained with ab9574. The recommended concentration ranges from 0.5 µg/ml-5.0 µg/ml. An HRP-labeled polymer detection system was used with DAB chromogen. Recommended antigen retrievals are heat induced antigen retrieval with a pH 6.0 Sodium Citrate buffer or enzyme induced antigen retrieval with Proteinase K. Optimal concentrations and conditions may vary.
Van Arsdale AR et al. Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. Cancer Med7:616-625 (2018).
Read more (PubMed: 29455465) »
Ireland L et al. Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer. Oncogene37:2022-2036 (2018).
Read more (PubMed: 29367764) »